aibioYDES YD Bio Ltd
YD Bio (YDES) news
YD Bio Ltd is a public biotech or pharmaceutical company listed on NASDAQ under the ticker YDES, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest YD Bio news
We have not published a story on YD Bio yet. When there is news, it will appear here.
What YD Bio does
YD Bio Ltd is a publicly listed biotechnology company that completed its business combination with Breeze and YD Biopharma on August 28, 2025. Its business covers regulated diagnostics, life science clinical services and healthcare product commercialization. Its oncology testing programs in the United States use DNA methylation-based tests offered as laboratory developed tests under a CLIA framework, with CLIA-certified and CAP-accredited laboratory partner EG BioMed. The company says it has not yet obtained FDA clearance or approval for any of its cancer detection test products and has not conducted clinical trials of them. It also provides regulated life science distribution and clinical trial supply chain services, ocular health product commercialization in the United States, and consumer healthcare distribution in Asia. It holds an exclusive sublicense to methylation analysis technology for breast cancer detection under a patent licensing and technology transfer agreement between EG BioMed Co., LTD. and Yong Ding Biopharm Co., Ltd. The company has also signed a non-binding memorandum of understanding to merge with EG BioMed, a letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., and a strategic alliance with YC Biotech Co., Ltd. on FDA submissions.
| Product or program | What it is | Stage |
|---|---|---|
| DNA methylation-based cancer detection tests | Oncology tests offered as laboratory developed tests to licensed providers | not yet FDA cleared or approved |
| EG Telehealth Platform | Online portal with a telehealth physician network to support diagnostic service delivery | launched March 31, 2026 |
| Clinical trial supply chain services | Procurement, logistics coordination and compliance support for clinical development |
YD Bio annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $596,817 | $510,360 |
| Research and development | $1.6 million | $491,353 |
| Net income (loss) | -$8.3 million | -$1.4 million |
| Cash from operations | -$6.6 million | -$1.2 million |
| Cash and equivalents | $6.0 million | $3.1 million |
Questions about YD Bio
What is the ticker symbol of YD Bio?
YD Bio Ltd trades under the ticker YDES on NASDAQ.
Where is YD Bio listed?
YD Bio Ltd is listed on NASDAQ.
Which country or territory is YD Bio listed under?
Our directory records YD Bio Ltd under United States.
Does aibio.space cover YD Bio?
aibio.space lists YD Bio Ltd among 2,820 public biotech companies and publishes its news here as stories appear.
What does YD Bio develop?
YD Bio Ltd is a publicly listed biotechnology company that completed its business combination with Breeze and YD Biopharma on August 28, 2025. Its business covers regulated diagnostics, life science clinical services and healthcare product commercialization.
What is DNA methylation-based cancer detection tests from YD Bio?
DNA methylation-based cancer detection tests: Oncology tests offered as laboratory developed tests to licensed providers Stage: not yet FDA cleared or approved.
What is EG Telehealth Platform from YD Bio?
EG Telehealth Platform: Online portal with a telehealth physician network to support diagnostic service delivery Stage: launched March 31, 2026.
What was YD Bio's revenue last year?
$596,817 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is YD Bio profitable?
YD Bio Ltd reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2025, and used $6.6 million of cash in operations, per its annual report to the SEC.
How much does YD Bio spend on research and development?
$1.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does YD Bio have?
$6.0 million in cash at Dec 31, 2025, per its 20-F.
Investor discussion: YD Bio
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
Listing details
- Company
- YD Bio Ltd
- Ticker
- YDES
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction